{"entity":{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","aka":["SELECT 1"],"tldr":"A phase 3 trial of Selumetinib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC is a phase 3 interventional study registered as NCT01933932 by AstraZeneca, with 510 participants enrolled, started 2013-09-25 and due to reach its primary completion in 2016-06-07. Interventions recorded: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF. Conditions listed: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV. Results were posted on ClinicalTrials.gov in 2017; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01933932","url":"https://clinicaltrials.gov/study/NCT01933932"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","kinase-inhibitors"],"targets":[],"drugs":["selumetinib","docetaxel"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct01933932-jama-2017"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01933932","phase":"3","setting":"A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)","sponsor":"AstraZeneca","started":"2013-09-25","startedType":"actual","yearReported":2017,"enrolled":510,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Selumetinib + Docetaxel","n":254,"value":3.9,"note":"IQR 1.5 to 5.9; Figures from the ClinicalTrials.gov results section (first posted 2017-08-29), not from a publication"},{"name":"Placebo + Docetaxel","n":256,"value":2.8,"note":"IQR 1.4 to 5.5"}],"hr":0.93,"ci":[0.77,1.12],"p":"0.4355","source":"https://clinicaltrials.gov/study/NCT01933932?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Selumetinib + Docetaxel","n":254,"value":8.7,"note":"IQR 3.6 to 16.8; Figures from the ClinicalTrials.gov results section (first posted 2017-08-29), not from a publication"},{"name":"Placebo + Docetaxel","n":256,"value":7.9,"note":"IQR 3.8 to 20.1"}],"hr":1.05,"ci":[0.85,1.3],"p":"0.6431","source":"https://clinicaltrials.gov/study/NCT01933932?tab=results"},{"endpoint":"Objective Response Rate (ORR)","unit":"participants","arms":[{"name":"Selumetinib + Docetaxel","n":254,"value":51,"note":"Figures from the ClinicalTrials.gov results section (first posted 2017-08-29), not from a publication"},{"name":"Placebo + Docetaxel","n":256,"value":35}],"p":"0.0515","source":"https://clinicaltrials.gov/study/NCT01933932?tab=results"}]},"route":"/trials/nct01933932/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"paper":[{"id":"paper-nct01933932-jama-2017","kind":"paper","name":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial","route":"/key-papers/paper-nct01933932-jama-2017/"}]}}